Menu Search
Equities

China Medical System Holdings Ltd

867:HKG.HS

China Medical System Holdings Ltd

Actions
  • Price (HKD)7.76
  • Today's Change-0.150 / -1.90%
  • Shares traded3.62m
  • 1 Year change-40.58%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.

  • Revenue in HKD (TTM)7.63bn
  • Net income in HKD1.51bn
  • Incorporated2006
  • Employees5.78k
  • Location
    China Medical System Holdings LtdUnit 2106, 21/F, Island Place Tower, 510, North Point Hong KongHKG
  • Phone+86 75 582416868
  • Fax+86 75 582416622
  • Websitehttps://web.cms.net.cn/zh/home/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.